Ascend Wellness Holdings (AAWH) Cash from Financing Activities (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Cash from Financing Activities came in at -$592000.0 in Q1 2026, down 104.32% year-on-year from $13.7 million in Q1 2025, and up 48.48% quarter-over-quarter from -$1.1 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$592000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 104.32% year-over-year to -$592000.0 in Q1 2026; TTM through Mar 2026 was -$9.2 million, a 78.29% decrease from a year earlier, with the FY2025 full-year figure at $5.1 million, up 125.09% from the prior year.
- Cash from Financing Activities improved to -$592000.0 in Q1 2026 per AAWH's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $54.7 million in Q2 2022 and bottomed at -$14.0 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is -$1.1 million (2025), against an average of $2.3 million.
- Across the five-year window, Cash from Financing Activities soared 1070.0% in 2022 and tumbled 6947.95% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $18.5 million in 2022, then sank by 99.61% to $73000.0 in 2023, then tumbled by 6947.95% to -$5.0 million in 2024, then jumped by 77.02% to -$1.1 million in 2025, then jumped by 48.48% to -$592000.0 in 2026.
- Per Business Quant, the three latest AAWH Cash from Financing Activities figures stand at -$592000.0 (Q1 2026), -$1.1 million (Q4 2025), and $6.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | -592,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -592,000.00 |
| Mar 31, 2026 | -592,000.00 |
| Dec 31, 2025 | -1.15 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | 13.69 Mn |
| Mar 31, 2025 | 13.69 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Mar 31, 2024 | -1.52 Mn |
| Mar 31, 2024 | -1.52 Mn |
| Dec 31, 2023 | 73,000.00 |
| Dec 31, 2023 | 73,000.00 |